Liquiritin Attenuates Lipopolysaccharides-Induced Cardiomyocyte Injury via an AMP-Activated Protein Kinase-Dependent Signaling Pathway

Liquiritin Attenuates Lipopolysaccharides-Induced Cardiomyocyte Injury via an AMP-Activated Protein Kinase-Dependent Signaling Pathway

Background: Liquiritin (LIQ) is a traditional Chinese medicine that has been reported to regulate inflammation, oxidative stress and cell apoptosis. However, the beneficial effects of LIQ in lipopolysaccharides (LPS)-induced septic cardiomyopathy (SCM) has not been reported. The primary goal of this...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Shan-Qi Mou, Zi-Ying Zhou, Hong Feng, Nan Zhang, Zheng Lin, Xiahenazi Aiyasiding, Wen-Jing Li, Wen Ding, Hai-Han Liao, Zhou-Yan Bian, Qi-Zhu Tang
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2021-05-01
Sarja:Frontiers in Pharmacology
Aiheet:
liquiritin
AMPKα
septic cardiomyopathy
inflammation
apoptosis
Linkit:https://www.frontiersin.org/articles/10.3389/fphar.2021.648688/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.648688/full

Samankaltaisia teoksia